GNLX

Genelux Corporation NASDAQ Listed Jan 26, 2023

Healthcare ·Biotechnology ·US · genelux.com

$2.83

Mkt Cap $106.5M

52w Low $2.29 8.6% of range 52w High $8.54

50d MA $2.65 200d MA $3.80

P/E (TTM) -3.2x

EV/EBITDA -4.9x

P/B 8.8x

Debt/Equity 0.1x

ROE -278.5%

P/FCF -6.1x

RSI (14) —

ATR (14) —

Beta 0.46

50d MA $2.65

200d MA $3.80

Avg Volume 196.4K

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

SIC Code

2834

CIK (SEC)

1231457

Phone

858 483 0024

2625 Townsgate Road · Westlake Village, CA 91361 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	-0.22	-0.24	-9.1%	2.54	-5.5%	-5.5%	+3.3%	-2.4%	+9.5%	-0.8%	—
Nov 5, 2025	AMC	-0.23	-0.21	+8.7%	7.84	-4.3%	-32.4%	+2.3%	+8.7%	+1.5%	-0.8%	—
Aug 7, 2025	AMC	-0.22	-0.20	+9.1%	3.34	+6.6%	-5.7%	+4.1%	-2.7%	+0.3%	+6.6%	—
May 6, 2025	AMC	-0.24	-0.21	+12.5%	2.33	+2.6%	-0.4%	+22.8%	+3.9%	-6.1%	-10.8%	—
Mar 28, 2025	AMC	-0.17	-0.26	-52.9%	3.08	-2.6%	-12.3%	-3.7%	-2.3%	-1.6%	-4.4%	—
Nov 14, 2024	AMC	-0.19	-0.19	+0.0%	2.94	+0.0%	-19.7%	+11.4%	-5.7%	+0.4%	-1.2%	—
Aug 14, 2024	AMC	-0.19	-0.22	-15.8%	2.09	+4.3%	+1.9%	-5.2%	+3.5%	-2.4%	+0.5%	—
May 9, 2024	AMC	-0.23	-0.29	-26.1%	4.02	-1.5%	-4.7%	-5.7%	-0.8%	+1.7%	-1.1%	—
Mar 29, 2024	AMC	-0.21	-0.25	-19.0%	—	—	—	—	—	—	—	—
Nov 14, 2023	AMC	-0.12	-0.20	-66.7%	14.59	-3.4%	-7.6%	-2.7%	-9.5%	-9.7%	-3.2%	—
Aug 14, 2023	AMC	-0.15	-0.23	-53.3%	22.87	+3.3%	+6.0%	-1.4%	-1.8%	+2.2%	-6.8%	—
May 15, 2023	AMC	-0.16	-0.53	-230.9%	23.19	-0.8%	+9.5%	-2.8%	+3.2%	+3.5%	-4.9%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$2.54	$2.40	-5.5%	-5.5%	+3.3%	-2.4%	+9.5%	-0.8%
May 8	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$2.32	$2.35	+1.3%	+22.8%	+3.9%	-6.1%	-10.8%	-3.2%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.08	$3.00	-2.6%	-12.3%	-3.7%	-2.3%	-1.6%	-4.4%
Mar 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.89	$3.50	-10.0%	-12.6%	-5.9%	-5.3%	+1.7%	-12.3%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.94	$2.94	+0.0%	-19.7%	+11.4%	-5.7%	+0.4%	-1.2%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.09	$2.18	+4.3%	+1.9%	-5.2%	+3.5%	-2.4%	+0.5%
Jun 3	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$2.71	$2.75	+1.5%	+3.7%	-8.5%	+0.8%	-2.7%	-9.5%
May 31	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$2.65	$2.70	+1.9%	+2.3%	+3.7%	-8.5%	+0.8%	-2.7%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.83	$3.89	+1.6%	-5.7%	-0.8%	+1.7%	-1.1%	+1.4%
Apr 3	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$5.25	$5.25	+0.0%	-7.4%	-2.7%	+4.2%	-5.3%	-1.5%
Apr 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.24	$5.19	-1.0%	+0.2%	-7.4%	-2.7%	+4.2%	-5.3%
Nov 24	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$11.19	$11.29	+0.9%	-0.8%	-2.1%	-3.8%	+11.9%	+1.7%
Jun 9	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$28.40	$28.98	+2.0%	-2.0%	+7.6%	+6.8%	+6.4%	+6.2%
May 18	Brookline Capital	Maintains	Hold → Hold	—	$24.70	$24.48	-0.9%	+3.2%	+3.5%	-4.9%	-3.5%	-3.9%
Feb 15	Benchmark	Maintains	Speculative Buy → Buy	—	$5.99	$6.01	+0.3%	+7.6%	-3.8%	+6.0%	+13.3%	+16.7%

Data updated apr 25, 2026 11:51am · Source: massive.com